Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03957876
Recruitment Status : Recruiting
First Posted : May 21, 2019
Last Update Posted : July 19, 2019
Sponsor:
Information provided by (Responsible Party):
Aziz Nazha, Case Comprehensive Cancer Center

Brief Summary:
The purpose of this study is to evaluate the efficacy of treatment with CPX-351 (an FDA approved drug for the treatment of AML) in individuals with MDS while using a new stratification tool to predict outcomes of participants following HMA failure. This approach is intended to gain a better understanding and insight into identifying new opportunities for drug approvals in this setting.

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndrome (MDS) Drug: CPX-351 Phase 2

Detailed Description:

This study will evaluate efficacy of treatment with CPX-351in participants with MDS while using a new stratification tool to predict outcomes of patients following HMA failure in order to gain a better understanding and insight into identifying new opportunities for drug approvals in this setting.

CPX-351is an investigational (experimental) drug for the indication of myelodysplastic syndrome that works by delivering two chemotherapy medications (daunorubicin and cytarabine) together which are then concentrated into the bone marrow (the part of the body that makes blood cells). CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA) for the indication of myelodysplastic syndrome. This drug is approved by theFDA for the indication of acute myeloid leukemia. One or more of the Investigators conducting this study serve as consultants for the company that makes products used in this study. These financial interests are within permissible limits established by the local institutional Conflict of Interest Policy.

Prior to beginning treatment, all eligible participants will be grouped into low risk versus high risk based on a stratification tool used to determine their disease. Group 1 will be low risk participants and group 2 will be high risk participants. All study participants will get the same study drug, CPX-351. Participants will receive the CPX-351 on days 1, 3 and 5 of the first 28 day cycle. After participants finish the first round of treatment and based on their response they may be eligible for another 4 cycles of treatment. The participant's doctor will inform them if this is an available option when the time comes. Once participant have finished treatment, their doctor will continue observe for side effects and follow their condition for 1 year.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of CPX-351 as a Novel Therapeutic Approach for Patients With Myelodysplastic Syndromes (MDS) After Hypomethylating Agent Failure
Actual Study Start Date : July 15, 2019
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : February 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: intravenous CPX-351 with potential maintenance therapy
Single agent CPX-351 administered at the standard FDA approved dose of 44 mg/m2 intravenously on days 1, 3, 5 of the induction cycle. If participants achieve complete remission (CR), complete remission with incomplete count recovery (CRi) or partial remission (PR), they will be eligible to continue on to maintenance therapy, which will consist of CPX351 at a dose of 15.4 mg/m2 every 28 days. Participants can receive up to 4 cycles of maintenance therapy.
Drug: CPX-351
CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
Other Name: (daunorubicin and cytarabine)




Primary Outcome Measures :
  1. Efficacy of CPX-351 as measured by overall response rate (ORR) [ Time Frame: day 28 +/- 7 days of induction ]
    Efficacy of CPX as measured by ORR as defined by IWG 2006 criteria for MDS participants at end of induction.


Secondary Outcome Measures :
  1. Time to response (TTR) associated with CPX-351 [ Time Frame: day 28 +/- 7 days of induction ]
    TTR associated with CPX-351 in participant with MDS at the end of induction. TTR defined by the time between starting the treatment and the time of achieving best response.

  2. Duration of response (DOR) in participants achieving a response [ Time Frame: At the end of cycle 1 (each cycle is 28 days), up to 1 year after end of treatment ]
    DOR in participants achieving a response defined by the time between first response (day C1 D28 +/-7 days from induction) and the day of loss of response

  3. Event-free survival (EFS) [ Time Frame: up to 1 year after end of treatment ]
    EFS probability of all participants enrolled in this trial from start of treatment and up to 1 year after the end of treatment.

  4. Overall survival (OS) [ Time Frame: up to 1 year after end of treatment ]
    OS probability of all participants enrolled in this trial from start of treatment and up to 1 year after the end of treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must give voluntary written consent before performance of any study related procedures not part of standard medical care
  • Diagnosis of MDS according to 2016 WHO criteria12
  • Primary therapy failure with either hypomethylating agents (decitabine or azacitidine) defined as:
  • Progression (according to 2006 IWG criteria)13 after initiation of azacitidine or decitabine treatment; or
  • Failure to achieve complete or partial response or hematological improvement (according to 2006 IWG)13 after at least 4-6 cycles (4-weeks cycle) of azacitidine or decitabine; or
  • Relapse after initial complete or partial response or hematological improvement (according to 2006 IWG criteria)13 observed after at least 4 cycles of azacitidine or decitabine.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status < 2
  • Subjects must have normal organ and marrow function defined as:
  • If total bilirubin < 2x upper limit of normal (</= 3 x ULN if considered to be due to leukemic involvement or Gilbert's syndrome) at the discretion of the treating physician following discussion with PI)
  • Serum Creatinine < 1.5 x ULN
  • LVEF >/= 50%
  • Female patients who:
  • Are postmenopausal for at least 1 year before the screening visit, OR
  • Are surgically sterile, OR
  • Agree to practice true abstinence from heterosexual contact or agree to use effective contraception without interruption during the study therapy and 90 days after the last dose
  • Male patients who:
  • Are surgically sterile, OR
  • Agree to practice true abstinence from heterosexual contact or agree to use effective contraception without interruption during the study therapy and 90 days after the last dose

Exclusion Criteria:

  • Prior treatment with CPX-351, or known hypersensitivity to CPX-351 or its components.
  • Prior treatment with intensive chemotherapy.
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that, in the view of the treating physician, would place the participant at an unacceptable risk if he or she were to participate in the study or would prevent that person from giving informed consent.
  • Any active malignancy (unrelated, non-hematological malignancy) diagnosed within the past 6 months of starting the study drug (other than curatively treated carcinoma-in-situ of the cervix or non-melanoma skin cancer).
  • Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Known history of HIV or active hepatitis B or C.
  • Major surgery within 2 weeks prior to study enrollment.
  • Pregnant or lactating females
  • Male and female patients who are fertile who do not agree to use an effective barrier methods of birth control (i.e. abstinence or 2 forms of contraception) to avoid pregnancy while receiving study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03957876


Contacts
Layout table for location contacts
Contact: Aziz Nazha, MD 866-223-8100 CancerCenterResearch@ccf.org

Locations
Layout table for location information
United States, Ohio
Cleveland Clinic, Case Comprehensive Cancer Center Recruiting
Cleveland, Ohio, United States, 44195
Contact: Aziz Nazha, MD    866-223-8100      
Sponsors and Collaborators
Case Comprehensive Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: Aziz Nazha, MD The Cleveland Clinic

Layout table for additonal information
Responsible Party: Aziz Nazha, Principal Investigator, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT03957876     History of Changes
Other Study ID Numbers: CASE2918
First Posted: May 21, 2019    Key Record Dates
Last Update Posted: July 19, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The study team does not plan to share IPD collected in this study

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cytarabine
Daunorubicin
Preleukemia
Myelodysplastic Syndromes
Syndrome
Disease
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors